)The top 100 stock
market authors
selected for publication
market authors
selected for publication
Ahithophel Weissberger » Comments » Single Comment
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
TraderMark
-
2
Don Dion
-
3
Cliff Wachtel
-
4
Mike Havrilla
-
5
James Quinn
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
Ertsfan:
Jun 12 15:12 pm
|Rating:
0
0
All Comments by Ahithophel Weissberger »Mannkind: Overlooked Biotech With Excellent Prospects (Part II) [View article]
Aerx (from Novo Nordisk) and Air (from Eli Lilly) were both dropped from development by Novo Nordisk and Eli Lilly earlier this year. As I said at the end of the article, I am planning to discuss some of the differences between Exubera and Technosphere Insulin in Part 3, the next installment of this series. Kos's inhaled insulin (now under the wings of Abbott Laboartories is very early in development (still in middle of Phase 2). Although I don't know much about it (they never released too much information about it), it doesn't have a chance of reaching the market for AT LEAST another 4 years.
As for the cancer rate in these other inhaled insulins, there has not been any signal of cancer in them. Abbott Laboratories published a press release saying that there was no increas in lung cancer and Aradigm (who co-developed Aerx with Novo Nordisk) also let out a press release that there was no lung cancer with Aerx.